Ruti Aga and the six-year ban: the fake family prescription outweighed the banned substance

On 10 September, the Athletics Integrity Unit announced its ruling on Ruti Aga: a six-year ban. A 32-year-old marathoner, the 2026 Tokyo Marathon champion, erased from every start line until she turns 38.

What made me stop at that statement was not the length of the sanction. It was the prescription.

According to the investigation, Aga produced a methylprednisolone prescription to explain her adverse analytical finding. The prescription was issued by a clinic that does not exist. The signing "doctor" was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace. The former workplace confirmed she had never worked there. The clinic, when asked, confirmed the prescription was not theirs.

Four independent layers of verification. Four denials. An evidentiary chain so tightly closed that no other reading survives. I read the statement four times, and only on the fourth did I see what separates this case from most doping cases I have followed in 34 years of writing.

To read Aga's case properly, she has to be placed in her correct stratum. Aga won the 2026 Tokyo Marathon, one of the six World Marathon Majors. She finished runner-up at World Marathon Majors three times. Across 2026–2026, that is the record of a genuine member of the world's top tier of women's road running, not a name filling out a start list.

The trigger event was a half marathon in China in March, which Aga won. The source does not disclose the time. For me, that means the sporting significance of that win cannot be assessed. Without a mark, there is no comparison to a personal best, no comparison to the field. Any inference about performance here is speculation.

Every excavation needs a verification point. In this case, the verification point is not the stopwatch but the classification of the substance.

Methylprednisolone is a synthetic glucocorticoid, a corticosteroid. It sits in WADA class S9, prohibited in-competition only, and is designated a Specified Substance. It is not an anabolic steroid. That detail is not trivial: class S9 and Specified Substance status determine the baseline sanction, and determine whether a therapeutic explanation can stand.

Most reports I read called methylprednisolone a "steroid." That wording pushes readers toward an entirely different class of substance, one bound up with muscle-building, performance fraud and systematic concealment. An anti-inflammatory for an aching knee and a muscle-building hormone share neither nature, nor baseline sanction, nor defensibility.

Aga stated she used the substance to treat a knee injury. That story is entirely possible.

What matters is this: if the story were true, and if a valid Therapeutic Use Exemption had been obtained through the proper process, the outcome could have differed. No violation. Or a violation at a lighter level, without aggravation. Route of administration, timing relative to competition, medical records, none of that is stated in the source, so I draw no conclusion. But the structure is clear: the substance half of this case was the soft half. The heavily punished half was something else.

Consider the arithmetic the AIU performed. Two years for presence of a prohibited substance in the sample. Four years for tampering with evidence during results management. Total: six years. Under the WADA Code, multiple anti-doping rule violations in one case are served consecutively, not concurrently. This is the point most readers skip when they see six years and assume a heavy doping sentence.

Four years for a forged document is double the two years for the substance in the urine sample. What was punished harder here was the concealment, not the use.

One organisational detail deserves recording. Aga's case was not adjudicated by a race organiser. It was investigated, results-managed and prosecuted by the Athletics Integrity Unit, World Athletics' independent integrity body, and resolved under the WADA Code. The scope of jurisdiction therefore was not limited to one race. It covered her entire competitive eligibility, across every series, in every country. A ruling from the AIU is not a ruling of one race; it is a ruling of a whole career.

The AIU's ability to verify this forgery chain was not luck. Prescription checks now involve direct confirmation with the issuing facility, cross-referencing the signatory's professional registration number, and cross-checking employment history. Three steps, done in days. Ten years ago a fake prescription could survive months. Now it does not survive the first week. Anyone weighing forged medical documents in 2026 is betting on a door that has already closed.

I have kept one rule since 2026: every article needs a method paragraph. Sample size, data source, and its limits. In Aga's case the only source is the AIU statement, and it has three large gaps. The year of the March adverse finding is not stated. The time of the Chinese half marathon is not stated. The route of administration is not stated. Those gaps do not change the conclusion on tampering, which four independent verifications established, but they bound what I am permitted to say about the medical half of the story.

Data has no memory, but I do.

In 2026, when the entire competition system froze, I spent nine months encoding 300 young athletes' files into tables of minutes played, injuries and monthly form trends. When the stadiums emptied, I could hear the footsteps of summer 2026 clearly. A pattern emerged from that table: the group whose minutes spiked more than 60 percent at ages 17–18 carried 2.4 times the ligament injury risk of the rest. Three hundred names in a dark vault, that is my excavation site.

I bring that table back for one reason: it taught me to separate endings caused by the body from endings caused by a decision. Aga is 32. For women's marathoners, the peak window commonly runs to 35 and beyond. She was inside that window, not past it. A six-year ban starting 10 September returns her to competition at roughly 38. Biologically, that is not impossible. Structurally, it almost never happens.

Set the case in a wider frame: women's marathon running operates on an Ethiopia–Kenya bipolar axis, and both sides carry enormous internal depth. One name removed from the leading group creates no gap in the field. That is why I say the Aga case barely moves the competitive balance of the women's marathon. It moves one career.

Financially, the consequences spread faster than the sanction. Annulment of the Chinese race result takes the prize money with it. Six years of ineligibility wipes out an elite marathoner's core revenue: appearance fees on the road circuit, major invitations, sponsorship contracts. Those contracts usually carry morality clauses. In doping cases, sponsors exit under exactly those clauses, and they exit fast.

Most doping cases end with a question about a substance. This one ends with a question about people.

A family member signed the form. An old prescription pad. A clinic invented from nothing. There was no organised doping operation here. There was an amateur cover-up, executed by people with no integrity expertise, failing at the first verification layer. That amateurism is the readable trace: it points to a gap in medical and legal support around the athlete.

In the East African road-running system, many athletes handle the legal side alone. No personal lawyer for sample-result cases. No one advising on TUEs. An athlete earning appearance fees on the road circuit may still have nobody to read a form for them. When something goes wrong, the instinct is to patch it with paperwork. And forged paperwork, in the current system, is caught far faster than a decade ago.

That is why I do not read this case as a story about Ethiopia. I read it as a story about the support profession.

To be clear: do not use the Aga case as evidence of a systemic problem in Ethiopian athletics. Ethiopia's road-running depth is so great that removing one entrant barely registers on the national output. That is the mark of a very thick talent production system, not a fraud system. An amateur, individual case pursued to the end is a mark of a testing mechanism that works.

What deserves more discussion is where the race took place. A half marathon in China in March, with prize money and appearance fees, is an environment where East African athletes cluster at high density and under lighter scrutiny than at the majors. The result of that race will almost certainly be annulled. The prize money will almost certainly be clawed back. That is a consequence of the road-racing economy, not only of a performance.

Six years from 10 September. An athlete of 32, with one major title and three major runner-up finishes, has no path back to the top after that layoff. Her career ended not because of a urine sample, but because of a piece of paper.

What I take away after re-reading the whole file: if Aga had been surrounded by someone who could read the rules, someone who knew a late TUE beats a fake prescription, what would we be discussing today? Probably a two-year ban. Or nothing at all.

No talent rises from a void; someone recorded it. Nor does any career vanish into a void. Someone recorded the collapse too.